概括
复合人体组织类型等离子体激活剂 (rt-PA) 在不稳定的心脏病患者中显著降低了持续的胸痛和冠状动脉血栓. 这种纤维溶解疗法为急性缺血事件提供了有前途的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 血栓溶解疗法 血栓溶解疗法
背景情况:
- 不稳定的胸痛 (Unstable angina pectoris,UAP) 是一种严重的病情,其特征是静止时胸痛和ST段偏差.
- 对UAP的标准医疗治疗包括β抑制剂,抗体,酸盐和肝素,但疗效可能是有限的.
研究的目的:
- 评估静脉注射复合人体组织类型等离子素激活剂 (rt-PA) 在治疗不稳定的胸痛时的疗效.
- 评估rt-PA对持续性缺血事件和冠状动脉血栓形成的影响.
主要方法:
- 一个随机的,盲目的研究,涉及24名UAP患者.
- 患者在标准医疗治疗的初始稳定后接受安慰剂或rt-PA (1.75 mg/kg超过12小时).
- 随访包括临床评估和冠状动脉血管学.
主要成果:
- 在治疗后,rt-PA显著降低了不稳定性心痛的持续性 (12名患者中的1人,与安慰剂组中的11名患者中的6人相比,p < .03).
- 冠状动脉扫描显示,在rt-PA治疗的患者中没有亚闭塞性血栓,相比之下,安慰剂组的11名患者中有8名 (p < .002).
结论:
- 静脉输入的rt-PA是有效的解决冠状动脉血栓和缓解不稳定的胸痛患者的症状.
- 用rt-PA进行纤维解质疗法代表了治疗急性冠状动脉综合征的有价值的治疗选择.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.